IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare ...
How do you market a drug for a disease that will make most people squirm? Well, Tarsus isn’t shying away from the topic and is going all out on its new campaign aimed at a condition caused by a skin ...
Tarsus is gearing up for a potential FDA green light of its experimental drug to treat a common but little-known eyelid inflammation disease and is wasting no time to boost awareness around the ...
Generated second quarter 2026 XDEMVY® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million ...
IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified ...
Tarsus Pharmaceuticals, Inc. (TARS) now has an approved product called XDEMVY, which is rapidly capturing the Demodex blepharitis market. The strong commercial launch is increasingly supporting ...
Tarsus Pharmaceuticals Inc. TARS on Wednesday acquired privately held iRenix Medical Inc., adding late-stage investigational ocular antiseptic IRX-101 to its ophthalmology pipeline. • Tarsus ...
Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year Increased full-year 2026 XDEMVY net product sales guidance to $685-705 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results